FDA exagamglogene autotemcel coverage for business development, investment, and market access teams
The FDA has approved Zynteglo, the first CRISPR gene therapy for sickle cell disease, offering new hope for patients with this debilitating condition.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
